Choosing the Right Adjuvant Chemotherapy Regimen

The selection of adjuvant chemotherapy after a modified radical mastectomy is critical, especially for patients with estrogen receptor (ER) negative breast cancer. ER-negative status indicates that the cancer's growth is not fueled by estrogen, making hormonal therapies ineffective and necessitating chemotherapy that directly targets cancer cells.

Rationale for ER-Negative Adjuvant Therapy

For ER-negative breast cancer, particularly in younger patients (like the 35-year-old described), the goal is to eliminate any residual cancer cells to reduce the risk of recurrence. Standard adjuvant regimens often include agents that are highly effective against aggressive tumor types. Anthracyclines, such as Adriamycin (Doxorubicin), are frequently incorporated into treatment plans for ER-negative disease due to their proven efficacy.

Commonly Used Regimen

Considering the options provided:

• Cyclophosphamide + 5-Fluro-uracil: Less potent compared to anthracycline-containing regimens for ER-negative disease.
• Cyclophosphamide + Methotrexate + 5-Fluoro-uracil (CMF): A historical standard, but often surpassed by anthracycline-based regimens in efficacy for ER-negative cases.
• Cyclophosphamide + Adriamycin + 5-Fluro-uracil (CAF): This regimen combines an alkylating agent (Cyclophosphamide), an anthracycline (Adriamycin), and an antimetabolite (5-Fluorouracil). It is a well-established and commonly used combination for adjuvant treatment of ER-negative breast cancer due to its effectiveness.
• Adriamycin + 5-Fluro-uracil (AF): Typically requires combination with another agent like Cyclophosphamide (forming ACF/CAF).

Therefore, the combination of Cyclophosphamide + Adriamycin + 5-Fluro-uracil is recognized as a standard and frequently utilized chemotherapy regimen in the adjuvant setting for ER-negative breast cancer following modified radical mastectomy.